Bibliography
- Wright V, Moll JM. Psoriatic arthritis. Bull Rheum Dis 1971;21(5):627-32
- Soscia E, Sirignano C, Catalano O, et al. New developments in magneticresonanceimaging of the nailunit. J Rheumatol Suppl 2012;89:49-53
- Costa L, Caso F, D’Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012;31(4):711-15
- Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl 2012;89:4-6
- Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25(8):1544-52
- Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion inpsoriatic arthritis. Immunol Res 2014;58(1):61-9
- Scarpa R, Atteno M, Lubrano E, et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 2011;30(8):1063-7
- Fiocco U, Sfriso P, Oliviero F, et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 2013;80(2):165-70
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382(9894):780-9
- Song IH, Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011;23:346-51
- Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48
- Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71(3):319-26
- Lories R, Vlam K. Tumor necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity. Expert Opin Biol Ther 2014;14(12):1825-36
- Atteno M, Costa L, Matarese A, et al. The use of TNF-alpha blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014;33(4):543-7
- Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014;33(2):273-6
- Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014;33(6):833-9